Fulcrum Therapeutics
Stock Forecast, Prediction & Price Target
Fulcrum Therapeutics Financial Estimates
Fulcrum Therapeutics Revenue Estimates
Fulcrum Therapeutics EBITDA Estimates
Fulcrum Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $19.16M N/A | $6.34M -66.90% | $2.80M -55.77% | Avg: $19.07M Low: $19.07M High: $19.07M avg. 580.16% | Avg: $85.12M Low: $85.12M High: $85.12M avg. 346.18% | Avg: $192.79M Low: $192.79M High: $192.79M avg. 126.47% | Avg: $279.99M Low: $279.99M High: $279.99M avg. 45.23% |
Net Income
% change YoY
| $-78.33M N/A | $-105.62M -34.83% | $-97.33M 7.84% | Avg: $-106.35M Low: $-174.73M High: $23.29M avg. -9.26% | Avg: $-92.78M Low: $-226.84M High: $99.93M avg. 12.75% | Avg: $-7.56M Low: $-7.56M High: $-7.56M avg. 91.85% | Avg: $54.97M Low: $54.97M High: $54.97M avg. 827.04% |
EBITDA
% change YoY
| $-81.05M N/A | $-111.70M -37.81% | $-108.49M 2.87% | Avg: $-11.44M Low: $-11.44M High: $-11.44M avg. 89.44% | Avg: $-51.07M Low: $-51.07M High: $-51.07M avg. -346.18% | Avg: $-115.67M Low: $-115.67M High: $-115.67M avg. -126.47% | Avg: $-167.99M Low: $-167.99M High: $-167.99M avg. -45.23% |
EPS
% change YoY
| -$2.22 N/A | -$2.35 -5.85% | -$1.59 32.34% | Avg: -$1.59 Low: -$2.85 High: $0.38 avg. 0.07% | Avg: -$1.22 Low: -$3.7 High: $1.63 avg. 23.36% | Avg: -$0.12 Low: -$0.12 High: -$0.12 avg. 89.87% | Avg: $0.9 Low: $0.9 High: $0.9 avg. 827.04% |
Operating Expenses
% change YoY
| $100.21M N/A | $118.47M 18.21% | $113.46M -4.22% | Avg: $97.95M Low: $97.95M High: $97.95M avg. -13.67% | Avg: $437.06M Low: $437.06M High: $437.06M avg. 346.18% | Avg: $989.86M Low: $989.86M High: $989.86M avg. 126.47% | Avg: $1.43B Low: $1.43B High: $1.43B avg. 45.23% |
FAQ
What is Fulcrum Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 230.59% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -174.73M, average is -106.35M and high is 23.29M.
What is Fulcrum Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 274.51% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $19.07M, average is $19.07M and high is $19.07M.
What is Fulcrum Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 235.09% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$2.85, average is -$1.59 and high is $0.38.
What is the best performing analyst?
In the last twelve months analysts have been covering Fulcrum Therapeutics stock. The most successful analyst is Kristen Kluska.